Is Adaptimmune Therapeutics PLC – ADR (ADAP) A Good Stock To Buy?

Judging by the fact that Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has experienced a decline in interest from the smart money, it’s easy to see that there were a few fund managers that elected to cut their positions entirely in the third quarter. At the top of the heap, Nick Niell’s Arrowgrass Capital Partners cut the biggest investment of the 700 funds monitored by Insider Monkey, valued at an estimated $8.8 million in stock, and Thomas Steyer’s Farallon Capital was right behind this move, as the fund dumped about $4.6 million worth. These moves are important to note, as total hedge fund interest was cut by 4 funds in the third quarter.

Let’s go over hedge fund activity in other stocks – not necessarily in the same industry as Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) but similarly valued. We will take a look at SL Industries, Inc. (NYSEMKT:SLI), Violin Memory Inc (NYSE:VMEM), Collectors Universe, Inc. (NASDAQ:CLCT), and Dixie Group Inc (NASDAQ:DXYN). This group of stocks’ market valuations match ADAP’s market valuation.

As you can see these stocks had an average of 6 hedge funds with bullish positions and the average amount invested in these stocks was $22 million. That figure was $46 million in ADAP’s case. Violin Memory Inc (NYSE:VMEM) is the most popular stock in this table. On the other hand Collectors Universe, Inc. (NASDAQ:CLCT) is the least popular one with only 5 bullish hedge fund positions. Compared to these stocks Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) is more popular among hedge funds. Considering that hedge funds are fond of this stock in relation to its market cap peers, it may be a good idea to analyze it in detail and potentially include it in your portfolio.